Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody

The clinical benefit of monotherapy involving immune checkpoint inhibitors (ICIs) such as anti-programmed death-1 antibody (PD-1 Ab) is limited to small populations. We previously developed a telomerase-specific oncolytic adenovirus, Telomelysin (OBP-301), the safety of which was confirmed in a phas...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Mol Ther
Autores principales: Kanaya, Nobuhiko, Kuroda, Shinji, Kakiuchi, Yoshihiko, Kumon, Kento, Tsumura, Tomoko, Hashimoto, Masashi, Morihiro, Toshiaki, Kubota, Tetsushi, Aoyama, Katsuyuki, Kikuchi, Satoru, Nishizaki, Masahiko, Kagawa, Shunsuke, Tazawa, Hiroshi, Mizuguchi, Hiroyuki, Urata, Yasuo, Fujiwara, Toshiyoshi
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Gene & Cell Therapy 2020
Materias:
Original Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7054725/
https://ncbi.nlm.nih.gov/pubmed/31991110
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ymthe.2020.01.003
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares